Psychostimulant addiction treatment

Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approva...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2014-12, Vol.87, p.150-160
Hauptverfasser: Phillips, Karran A., Epstein, David H., Preston, Kenzie L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 160
container_issue
container_start_page 150
container_title Neuropharmacology
container_volume 87
creator Phillips, Karran A.
Epstein, David H.
Preston, Kenzie L.
description Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions. This article is part of the Special Issue entitled ‘CNS Stimulants’. •Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.
doi_str_mv 10.1016/j.neuropharm.2014.04.002
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4524548</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390814001282</els_id><sourcerecordid>24727297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</originalsourceid><addsrcrecordid>eNqFkEtLAzEQx4Motla_ghQ87zp57CZ7EbT4goIe9ByyydSmdHdLNi3025tSrXoSBgZm_g_4ETKmkFOg5fUib3EdutXchCZnQEUOaYAdkSFVkmcSSnFMhumiMl6BGpCzvl8AgFBUnZIBE5JJVskhuXrtt3be9dE366Vp49g45230XTuOAU1ssI3n5GRmlj1efO0ReX-4f5s8ZdOXx-fJ7TSzhahihmAdGFsoh4JWtZgZMPXMMQsSK6ek4ihrtAw4KMYqTq1waIrC8LKkinM-Ijf73NW6btDZVB3MUq-Cb0zY6s54_ffT-rn-6DZaFEwUQqUAtQ-woev7gLODl4LegdML_QNO78BpSAMsWS9_dx-M36SS4G4vwERg4zHo3npsLTof0EbtOv9_yydCxYZf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psychostimulant addiction treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Phillips, Karran A. ; Epstein, David H. ; Preston, Kenzie L.</creator><creatorcontrib>Phillips, Karran A. ; Epstein, David H. ; Preston, Kenzie L.</creatorcontrib><description>Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions. This article is part of the Special Issue entitled ‘CNS Stimulants’. •Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2014.04.002</identifier><identifier>PMID: 24727297</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Addiction ; Central Nervous System Stimulants - administration &amp; dosage ; Central Nervous System Stimulants - pharmacokinetics ; Humans ; Psychostimulant ; Randomized Controlled Trials as Topic ; Self Administration ; Substance Withdrawal Syndrome - physiopathology ; Substance Withdrawal Syndrome - therapy ; Substance-Related Disorders - physiopathology ; Substance-Related Disorders - therapy ; Treatment</subject><ispartof>Neuropharmacology, 2014-12, Vol.87, p.150-160</ispartof><rights>2014</rights><rights>Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</citedby><cites>FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0028390814001282$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24727297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Phillips, Karran A.</creatorcontrib><creatorcontrib>Epstein, David H.</creatorcontrib><creatorcontrib>Preston, Kenzie L.</creatorcontrib><title>Psychostimulant addiction treatment</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions. This article is part of the Special Issue entitled ‘CNS Stimulants’. •Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.</description><subject>Addiction</subject><subject>Central Nervous System Stimulants - administration &amp; dosage</subject><subject>Central Nervous System Stimulants - pharmacokinetics</subject><subject>Humans</subject><subject>Psychostimulant</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Self Administration</subject><subject>Substance Withdrawal Syndrome - physiopathology</subject><subject>Substance Withdrawal Syndrome - therapy</subject><subject>Substance-Related Disorders - physiopathology</subject><subject>Substance-Related Disorders - therapy</subject><subject>Treatment</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEQx4Motla_ghQ87zp57CZ7EbT4goIe9ByyydSmdHdLNi3025tSrXoSBgZm_g_4ETKmkFOg5fUib3EdutXchCZnQEUOaYAdkSFVkmcSSnFMhumiMl6BGpCzvl8AgFBUnZIBE5JJVskhuXrtt3be9dE366Vp49g45230XTuOAU1ssI3n5GRmlj1efO0ReX-4f5s8ZdOXx-fJ7TSzhahihmAdGFsoh4JWtZgZMPXMMQsSK6ek4ihrtAw4KMYqTq1waIrC8LKkinM-Ijf73NW6btDZVB3MUq-Cb0zY6s54_ffT-rn-6DZaFEwUQqUAtQ-woev7gLODl4LegdML_QNO78BpSAMsWS9_dx-M36SS4G4vwERg4zHo3npsLTof0EbtOv9_yydCxYZf</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Phillips, Karran A.</creator><creator>Epstein, David H.</creator><creator>Preston, Kenzie L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20141201</creationdate><title>Psychostimulant addiction treatment</title><author>Phillips, Karran A. ; Epstein, David H. ; Preston, Kenzie L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-e0cd0ac58de419b4fa0abfd2c07e9d8783e7bec2030822931c4dea55a36618333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Addiction</topic><topic>Central Nervous System Stimulants - administration &amp; dosage</topic><topic>Central Nervous System Stimulants - pharmacokinetics</topic><topic>Humans</topic><topic>Psychostimulant</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Self Administration</topic><topic>Substance Withdrawal Syndrome - physiopathology</topic><topic>Substance Withdrawal Syndrome - therapy</topic><topic>Substance-Related Disorders - physiopathology</topic><topic>Substance-Related Disorders - therapy</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Phillips, Karran A.</creatorcontrib><creatorcontrib>Epstein, David H.</creatorcontrib><creatorcontrib>Preston, Kenzie L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Phillips, Karran A.</au><au>Epstein, David H.</au><au>Preston, Kenzie L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychostimulant addiction treatment</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>87</volume><spage>150</spage><epage>160</epage><pages>150-160</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions. This article is part of the Special Issue entitled ‘CNS Stimulants’. •Stimulant-use disorders remain prevalent.•Stimulant-use disorders can result in both short- and long-term adverse consequences.•No pharmacological intervention with regulatory approval or generally accepted use.•The mainstay of treatment remains behavioral interventions.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24727297</pmid><doi>10.1016/j.neuropharm.2014.04.002</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2014-12, Vol.87, p.150-160
issn 0028-3908
1873-7064
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4524548
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Addiction
Central Nervous System Stimulants - administration & dosage
Central Nervous System Stimulants - pharmacokinetics
Humans
Psychostimulant
Randomized Controlled Trials as Topic
Self Administration
Substance Withdrawal Syndrome - physiopathology
Substance Withdrawal Syndrome - therapy
Substance-Related Disorders - physiopathology
Substance-Related Disorders - therapy
Treatment
title Psychostimulant addiction treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A53%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychostimulant%20addiction%20treatment&rft.jtitle=Neuropharmacology&rft.au=Phillips,%20Karran%20A.&rft.date=2014-12-01&rft.volume=87&rft.spage=150&rft.epage=160&rft.pages=150-160&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2014.04.002&rft_dat=%3Cpubmed_cross%3E24727297%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24727297&rft_els_id=S0028390814001282&rfr_iscdi=true